SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 203.76 |
| Enterprise Value ($M) | 195.16 |
| Book Value ($M) | 150.50 |
| Book Value / Share | 12.36 |
| Price / Book | 1.35 |
| NCAV ($M) | 147.22 |
| NCAV / Share | 12.09 |
| Price / NCAV | 1.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.23 |
| Return on Assets (ROA) | -1.07 |
| Return on Equity (ROE) | -124.43 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 13.84 |
| Current Ratio | 13.84 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 160.89 |
| Assets | 164.17 |
| Liabilities | 13.67 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Cormorant Asset Management, LP | 19.50 | 17.28 | |
| 13G/A | Tang Capital Management Llc | 4.98 | ||
| 13G/A | Point72 Asset Management, L.P. | 0.00 | -100.00 | |
| 13G/A | K2 HealthVentures Equity Trust LLC | 0.02 | -99.16 | |
| 13G | Orbimed Advisors Llc | 4.90 | ||
| 13G/A | Adage Capital Management, L.P. | 4.39 | ||
| 13G/A | Vanguard Group Inc | 5.36 | 0.00 | |
| 13G | BlackRock, Inc. | 6.70 | 0.00 | |
| 13G/A | Millennium Management Llc | 1.00 | -77.45 | |
| 13G | Octagon Capital Advisors LP | 9.30 | ||
| 13G | Paradigm Biocapital Advisors LP | 0.00 | -100.00 | |
| 13G | Ra Capital Management, L.p. | 4.10 | ||
| 13G | Adage Capital Partners Gp, L.l.c. | 7.70 | ||
| 13G | Integrated Core Strategies (us) Llc | 4.10 | ||
| 13G | Cormorant Global Healthcare Master Fund, LP | 14.27 | ||
| 13G | Tang Capital Partners Lp | 9.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 43,233 | 160,326 | 26.97 | |
| 62,321 | 225,730 | 27.61 | |
| 68,371 | 236,351 | 28.93 | |
| 104,490 | 262,719 | 39.77 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CORT – Corcept Therapeutics Incorporated | COYA – Coya Therapeutics, Inc. |
| CPRX – Catalyst Pharmaceuticals, Inc. | CRDF – Cardiff Oncology, Inc. |
| CRIS – Curis, Inc. |